Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

@article{Goss2005RandomizedTO,
  title={Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.},
  author={Paul E. Goss and James N. Ingle and Silvana Martino and Nicholas J. Robert and Hyman B. Muss and Martine J Piccart and Monica Castiglione and Dongsheng Tu and Lois E. Shepherd and Kathleen I. Pritchard and Robert B. Livingston and Nancy E. Davidson and Larry Norton and Edith A. Perez and Jeffrey S. Abrams and David A Cameron and Michael J. Palmer and Joseph L Pater},
  journal={Journal of the National Cancer Institute},
  year={2005},
  volume={97 17},
  pages={
          1262-71
        }
}
BACKGROUND Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduces the risk of such late recurrences, was stopped early after an interim analysis showed that letrozole improved disease-free survival. This report presents updated findings from the trial. METHODS Postmenopausal women completing 5 years… 

Figures and Tables from this paper

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
TLDR
The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
  • P. Goss, J. Ingle, D. Tu
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
interpretation of this cohort analysis suggests that LET improves DFS and distant DFS even when there has been a substantial period of time since the discontinuation of prior adjuvant tamoxifen.
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
  • P. Dubsky, R. Jakesz, M. Gnant
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Despite a low overall rate of recurrence in a population with breast cancer at limited risk of relapse, the a priori sequence strategy of 2 years of TAM followed by 3 years of ANA led to small outcome and toxicity benefits.
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
TLDR
Original exemestane assignment resulted in non-statistically significant improvement in DFS and in statisticallysignificant improvement in RFS, and toxicity, assessed up to time of unblinding, was acceptable for the adjuvant setting.
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
TLDR
These data confirm the benefit of extending adjuvant tamoxifen therapy beyond 5 years with anastrozole compared with no further treatment and investigate the possibility of tailoring this period to suit different disease types.
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
  • P. Goss, J. Ingle, J. Pater
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
These results suggest greater benefit for letrozole in DFS, DDFS, and OS in patients with ER+/PgR+ tumors, implying greater activity of letroZole in tumors with a functional ER.
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12).
TLDR
Adjuvant tamoxifen, given after chemotherapy to premenopausal women with EBC, improved 5-year DFS and poor compliance may have reduced treatment efficacy.
Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer
TLDR
Physicians and patients now have multiple evidence-based treatment options for women who complete 5 years of adjuvant endocrine therapy and decision based on menopausal status, individual risk, tolerance and magnitude of potential benefit should be considered for all.
Reducing the Risk of Distant Metastases: A Better End Point in Adjuvant Aromatase Inhibitor Breast Cancer Trials?
TLDR
Whether significant improvements in DDFS correlate with meaningful improvements in OS or breast cancer-associated mortality is explored and may be a quicker, better end point in clinical trials, leading to a more efficient, faster assessment of treatment efficacy.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
TLDR
A randomized trial was performed to assess the efficacy of maintaining tamoxifen therapy beyond 5 years in women with axillary lymph node-positive breast cancer who had been treated with surgery followed by 1 year of chemotherapy and 5 years of tamox ifen, and found no statistically significant differences.
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
TLDR
As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
TLDR
The outcome of patients in the B-14 trial through 10 years of follow-up indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease, and questions arose about how long the observed benefit would persist.
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
TLDR
Overall and disease-free survival results indicate that delayed adjuvant tamoxifen administration (30 mg/day) is justified in women with early breast cancer, even if this treatment is initiated two or more years after primary treatment.
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
TLDR
Exemestane therapy after two to three years ofTamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxIFen treatment.
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
TLDR
Through 7 years of follow-up after rerandomization, there continues to be no additional benefit from tamoxifen administered beyond 5 years in women with ER-positive breast cancer and negative axillary lymph nodes.
The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group
  • B. Ma, A. Oza, A. Fyles
  • Medicine
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2004
TLDR
In conclusion, letrozole is well tolerated but has little overall activity in this cohort of women with endometrial cancer.
Survival Analysis: Techniques for Censored and Truncated Data
Survival analysis:techniques for censored and truncated data , Survival analysis:techniques for censored and truncated data , کتابخانه مرکزی دانشگاه علوم پزشکی ایران
...
...